NervGen Pharma (NGEN) News
NASDAQ: NGENHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.85-0.075 (-3.91%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NGEN news summary
We found 4 recent headlines mentioning NervGen Pharma (NGEN): 2 in the past week and 3 in the past 30 days, most often from GlobeNewswire. For price context, NGEN is down 3.91% at $1.85. The most recent story, "NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer", was published by GlobeNewswire on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest NervGen Pharma headlines
- NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical OfficerMIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…GlobeNewswire
- NervGen Reports Third Quarter 2026 Financial Results and Provides Business UpdatesMIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…GlobeNewswire
- NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord InjuryMIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)…GlobeNewswire
- NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord InjuryNervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic…GlobeNewswire